CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Overview
Canada - TSX:CRDL - CA14161Y2006 - Common Stock
CRDL.CA Key Statistics, Chart & Performance
The current stock price of CRDL.CA is 1.45 CAD. In the past month the price decreased by -5.23%. In the past year, price decreased by -45.49%.
CRDL.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.73 | 3.39B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 2.52B | ||
| CRON.CA | CRONOS GROUP INC | 51.71 | 1.39B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.93 | 822.33M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 580.96M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 502.95M | ||
| TSND.CA | TERRASCEND CORP | N/A | 447.39M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 446.06M | ||
| HITI.CA | HIGH TIDE INC | N/A | 438.88M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 25.3 | 409.93M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 349.26M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 263.08M |
Related stock screener links
About CRDL.CA
Company Profile
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Company Info
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO L6H 0G5 CA
CEO: David G. Elsley
Employees: 18
Phone: 12899100850
CARDIOL THERAPEUTICS INC-A / CRDL.CA FAQ
What is the stock price of CARDIOL THERAPEUTICS INC-A today?
The current stock price of CRDL.CA is 1.45 CAD. The price decreased by -3.33% in the last trading session.
What is the ticker symbol for CARDIOL THERAPEUTICS INC-A stock?
The exchange symbol of CARDIOL THERAPEUTICS INC-A is CRDL and it is listed on the Toronto Stock Exchange exchange.
On which exchange is CRDL.CA stock listed?
CRDL.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for CARDIOL THERAPEUTICS INC-A stock?
8 analysts have analysed CRDL.CA and the average price target is 9.95 CAD. This implies a price increase of 585.86% is expected in the next year compared to the current price of 1.45. Check the CARDIOL THERAPEUTICS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARDIOL THERAPEUTICS INC-A worth?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) has a market capitalization of 124.61M CAD. This makes CRDL.CA a Micro Cap stock.
How many employees does CARDIOL THERAPEUTICS INC-A have?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) currently has 18 employees.
What are the support and resistance levels for CARDIOL THERAPEUTICS INC-A (CRDL.CA) stock?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) has a support level at 1.39 and a resistance level at 1.51. Check the full technical report for a detailed analysis of CRDL.CA support and resistance levels.
Should I buy CARDIOL THERAPEUTICS INC-A (CRDL.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRDL.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRDL.CA, evaluating the profitability, health, valuation and growth aspects
- CARDIOL THERAPEUTICS INC-A (CRDL.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARDIOL THERAPEUTICS INC-A (CRDL.CA) Sales and EPS estimates to see what analysts future expectations are.
- CARDIOL THERAPEUTICS INC-A (CRDL.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARDIOL THERAPEUTICS INC-A (CRDL.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Chart to make your own analysis
- CARDIOL THERAPEUTICS INC-A (CRDL.CA) Latest news and press-releases to stay up to date.
Does CARDIOL THERAPEUTICS INC-A (CRDL.CA) stock pay dividends?
CRDL.CA does not pay a dividend.
When does CARDIOL THERAPEUTICS INC-A (CRDL.CA) report earnings?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of CARDIOL THERAPEUTICS INC-A (CRDL.CA)?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
CRDL.CA Technical Analysis
CRDL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRDL.CA. The financial health of CRDL.CA is average, but there are quite some concerns on its profitability.
CRDL.CA Financial Highlights
Over the last trailing twelve months CRDL.CA reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -140.58% | ||
| ROE | -203.47% | ||
| Debt/Equity | 0.01 |
CRDL.CA Forecast & Estimates
8 analysts have analysed CRDL.CA and the average price target is 9.95 CAD. This implies a price increase of 585.86% is expected in the next year compared to the current price of 1.45.